In contrast, polyreactive HLA-E mAbs cross react with three or more of the other loci of HLA class-I, namely HLA-A, HLA-B, HLA-C, HLA-F, and HLA-G, which is similar to commercially available mAbs (such as MEM-E0/2, MEM- E0/6, MEM-E0/7, MEM-E0/8 and 3D12), Therefore, the monospecific anti-HLA-E mAbs are better able to confirm specific HLA-E expression on tumor cells and biopsies obtained from cancer patients. This evidence concerns the gene HLA-C and cancer.